{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:41:40Z","timestamp":1760762500286,"version":"build-2065373602"},"reference-count":48,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5129-24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:42Z","timestamp":1744394982000},"page":"2934-2943","source":"Crossref","is-referenced-by-count":0,"title":["The Serum \u03b3-Glutamyltransferase Level Is Associated with the Development of Hypertension in Alcohol Infrequent Drinkers but Not in Frequent Drinkers"],"prefix":"10.2169","volume":"64","author":[{"given":"Kazuma","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Immunology and Microbiology, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marenao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan"},{"name":"Tanaka Medical Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Public Health, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagisa","family":"Hanawa","sequence":"additional","affiliation":[{"name":"Department of Health Checkup and Promotion, Keijinkai Maruyama Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1: 15080, 2015.","DOI":"10.1038\/nrdp.2015.80"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension 75: 275-284, 2020.","DOI":"10.1161\/HYPERTENSIONAHA.119.13419"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 18: 599-612, 2021.","DOI":"10.1038\/s41575-021-00448-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 13: 297-310, 2017.","DOI":"10.1038\/nrneph.2017.16"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 73: 948-963, 2019.","DOI":"10.1016\/j.jacc.2018.11.050"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73: 202-209, 2020.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mori K, Tanaka M, Hosaka I, et al. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. Hypertens Res 46: 1110-1121, 2023.","DOI":"10.1038\/s41440-023-01179-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tanaka M, Mori K, Takahashi S, et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant 38: 700-711, 2023.","DOI":"10.1093\/ndt\/gfac188"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res 51: 1115-1128, 2021.","DOI":"10.1111\/hepr.13685"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38: 263-355, 2001.","DOI":"10.1080\/20014091084227"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamada Y, Ikai E, Tsuritani I, Ishizaki M, Honda R, Ishida M. The relationship between serum gamma-glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers. Hypertens Res 18: 295-301, 1995.","DOI":"10.1291\/hypres.18.295"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee DH, Jacobs DR Jr, Gross M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49: 1358-1366, 2003.","DOI":"10.1373\/49.8.1358"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 46: 1186-1193, 2005.","DOI":"10.1161\/01.HYP.0000185688.81320.4d"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cheung BM, Ong KL, Tso AW, et al. Gamma-glutamyl transferase level predicts the development of hypertension in Hong Kong Chinese. Clin Chim Acta 412: 1326-1331, 2011.","DOI":"10.1016\/j.cca.2011.03.030"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lee DH, Ha MH, Kim JR, Gross M, Jacobs DR Jr. Gamma-glutamyltransferase, alcohol, and blood pressure. A four year follow-up study. Ann Epidemiol 12: 90-96, 2002.","DOI":"10.1016\/S1047-2797(01)00252-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kim NH, Huh JK, Kim BJ, Kim MW, Kim BS, Kang JH. Serum gamma-glutamyl transferase level is an independent predictor of incident hypertension in Korean adults. Clin Exp Hypertens 34: 402-409, 2012.","DOI":"10.3109\/10641963.2012.665539"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis. PLoS One 7: e48878, 2012.","DOI":"10.1371\/journal.pone.0048878"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mori K, Furuhashi M, Tanaka M, et al. U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2. Hypertens Res 44: 107-116, 2021.","DOI":"10.1038\/s41440-020-0532-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marugame T, Yamamoto S, Yoshimi I, Sobue T, Inoue M, Tsugane S; Japan Public Health Center-based Prospective Study G. Patterns of alcohol drinking and all-cause mortality: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 165: 1039-1046, 2007.","DOI":"10.1093\/aje\/kwk112"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 42: 1235-1481, 2019.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 40 (Suppl 1): S11-S24, 2017.","DOI":"10.2337\/dc17-S005"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Matsuzawa Y. Metabolic syndrome - definition and diagnostic criteria in Japan. J Atheroscler Thromb 12: 301, 2005.","DOI":"10.5551\/jat.12.301"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102: 2708-2715, 2007.","DOI":"10.1111\/j.1572-0241.2007.01526.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mori K, Tanaka M, Sato T, et al. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Hepatol Res 55: 34-45, 2025.","DOI":"10.1111\/hepr.14097"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mori K, Furuhashi M, Tanaka M, et al. Serum uric acid level is associated with an increase in systolic blood pressure over time in female subjects: Linear mixed-effects model analyses. Hypertens Res 45: 344-353, 2022.","DOI":"10.1038\/s41440-021-00792-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol 110: 63-73, 2019.","DOI":"10.1016\/j.jclinepi.2019.02.016"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. van Buuren S, Groothuis-Oudshoorn K. Mice: Multivariate imputation by chained equations in R. J Stat Softw 45: 1-67, 2011.","DOI":"10.18637\/jss.v045.i03"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. von Hippel PT. How many imputations do you need? A two-stage calculation using a quadratic rule. Sociol Methods Res 49: 699-718, 2018.","DOI":"10.1177\/0049124117747303"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Peana AT, Sanchez-Catalan MJ, Hipolito L, et al. Mystic acetaldehyde: the never-ending story on alcoholism. Front Behav Neurosci 11: 81, 2017.","DOI":"10.3389\/fnbeh.2017.00081"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Sambu S, Hemaram U, Murugan R, Alsofi AA. Toxicological and teratogenic effect of various food additives: an updated review. Biomed Res Int 2022: 6829409, 2022.","DOI":"10.1155\/2022\/6829409"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52: 1156-1161, 2010.","DOI":"10.1002\/hep.23789"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174, 2006.","DOI":"10.1016\/j.jhep.2006.02.011"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yilmaz MI, Turgut F, Kanbay M, et al. Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease. Int Urol Nephrol 45: 1071-1078, 2013.","DOI":"10.1007\/s11255-012-0354-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev 40: 1367-1393, 2019.","DOI":"10.1210\/er.2019-00034"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Satou R, Penrose H, Navar LG. Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep 20: 100, 2018.","DOI":"10.1007\/s11906-018-0900-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276, 2004.","DOI":"10.1172\/JCI20945"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093, 2004.","DOI":"10.1126\/science.1104742"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 38: 535-539, 2004.","DOI":"10.1080\/10715760410001694026"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Teschke R, Neuefeind M, Nishimura M, Strohmeyer G. Hepatic gamma-glutamyltransferase activity in alcoholic fatty liver: comparison with other liver enzymes in man and rats. Gut 24: 625-630, 1983.","DOI":"10.1136\/gut.24.7.625"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. van Beek J, de Moor MHM, Geels LM, et al. The association of alcohol intake with gamma-glutamyl transferase (GGT) levels: evidence for correlated genetic effects. Drug Alcohol Depend 134: 99-105, 2014.","DOI":"10.1016\/j.drugalcdep.2013.09.016"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Sugiyama A, Kurisu A, Ouoba S, et al. Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019. Liver Int 41: 2914-2923, 2021.","DOI":"10.1111\/liv.15055"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Wu X, Liang D, Sun J, Lin Y, Wu S. Association between sex-specific serum gamma-glutamyltransferase and incidence of hypertension in a Chinese population without metabolic syndrome: a prospective observational study. Front Cardiovasc Med 8: 644044, 2021.","DOI":"10.3389\/fcvm.2021.644044"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kunutsor SK, Apekey TA, Cheung BM. Gamma-glutamyltransferase and risk of hypertension: a systematic review and dose-response meta-analysis of prospective evidence. J Hypertens 33: 2373-2381, 2015.","DOI":"10.1097\/HJH.0000000000000763"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int 36: 1723-1734, 2016.","DOI":"10.1111\/liv.13221"},{"key":"47","unstructured":"47. Ruiz-Larrea MB, Leal AM, Martin C, Martinez R, Lacort M. Antioxidant action of estrogens in rat hepatocytes. Rev Esp Fisiol 53: 225-229, 1997."},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Borras C, Gambini J, Gomez-Cabrera MC, et al. 17\u03b2-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2<sup>MAPK<\/sup>\/NF\u03baB cascade. Aging Cell 4: 113-118, 2005.","DOI":"10.1111\/j.1474-9726.2005.00151.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5129-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:06Z","timestamp":1760761626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5129-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":48,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5129-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5129-24"}}